Abstract
t(8;21) and t(16;21) create two fusion proteins, AML-1–ETO and AML-1–MTG16, respectively, which fuse the AML-1 DNA binding domain to putative transcriptional corepressors, ETO and MTG16. Here, we show that distinct domains of ETO contact the mSin3A and N-CoR corepressors and define two binding sites within ETO for each of these corepressors. In addition, of eight histone deacetylases (HDACs) tested, only the class I HDACs HDAC-1, HDAC-2, and HDAC-3 bind ETO. However, these HDACs bind ETO through different domains. We also show that the murine homologue of MTG16, ETO-2, is also a transcriptional corepressor that works through a similar but distinct mechanism. Like ETO, ETO-2 interacts with N-CoR, but ETO-2 fails to bind mSin3A. Furthermore, ETO-2 binds HDAC-1, HDAC-2, and HDAC-3 but also interacts with HDAC-6 and HDAC-8. In addition, we show that expression of AML-1–ETO causes disruption of the cell cycle in the G1 phase. Disruption of the cell cycle required the ability of AML-1–ETO to repress transcription because a mutant of AML-1–ETO, Δ469, which removes the majority of the corepressor binding sites, had no phenotype. Moreover, treatment of AML-1–ETO-expressing cells with trichostatin A, an HDAC inhibitor, restored cell cycle control. Thus, AML-1–ETO makes distinct contacts with multiple HDACs and an HDAC inhibitor biologically inactivates this fusion protein.
ACKNOWLEDGMENTS
We thank Yue Hou and Dana King for expert technical assistance and the Vanderbilt Ingram Cancer Center sequencing facility for support.
This work was supported by National Institutes of Health grants RO1-CA76186 (SM), RO1-AG13726, RO1-CA64140, and RO1-CA77274, American Cancer Society grants JFRA-591 (S.W.H.) and PO1 CA71907 (J.R.D.), and a Center grant from the National Cancer Institute (CA68485), the Vanderbilt-Ingram Cancer Center, and the American Lebanese Syrian Associated Charities of St. Jude Children's Research Hospital. J.N. is a Leukemia Society of America Special Fellow (grant 3827-99).